Zhou Yangyang, Zheng Shimeng, Guo Qihang, Wei Ning, Xiao Zhuanglong, Song Yuhu
Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Immunology Research Center for Oral and Systemic Health, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Transl Cancer Res. 2024 Feb 29;13(2):847-863. doi: 10.21037/tcr-23-1474. Epub 2024 Feb 27.
Hepatocellular carcinoma (HCC) is a primary liver cancer with high mortality worldwide. Even though the patients with HCC received standard therapies, patients with HCC continue to experience unsatisfactory therapy outcomes. Presently, immune therapy acts as a novel therapeutic management for HCC. The aim of this study was to determine overexpressed genes in HCC and evaluate the association between overexpressed genes with the prognosis and immune infiltration.
Gene expression profiles of HCC were analyzed using multiple online databases, and then confirmed by qualitative real time-polymerase chain reaction (RT-qPCR) and immunohistochemical analysis. The correlations of gene overexpression with the prognosis and immune infiltration were determined.
Top 11 common differentially expressed genes were identified in HCC, and RACGAP1 was selected for further analysis. RACGAP1 expression was significantly higher in HCC tissues than that in normal tissues. Upregulation of RACGAP1 was correlated with clinical stage and poor prognosis. Additionally, RACGAP1 overexpression was positively related to the infiltration of suppressive immune cells. Moreover, we speculate RACGAP1 may promote tumorigenesis of HCC through immunosuppression mediated by YAP activation.
Overexpression of RACGAP1 was associated with unfavorable prognosis and immune infiltration in HCC, which indicated that RACGAP1 could be a molecular target for HCC.
肝细胞癌(HCC)是一种在全球范围内死亡率很高的原发性肝癌。尽管HCC患者接受了标准治疗,但HCC患者的治疗效果仍然不尽人意。目前,免疫疗法是HCC的一种新型治疗手段。本研究的目的是确定HCC中过表达的基因,并评估过表达基因与预后及免疫浸润之间的关联。
使用多个在线数据库分析HCC的基因表达谱,然后通过实时定量聚合酶链反应(RT-qPCR)和免疫组织化学分析进行验证。确定基因过表达与预后及免疫浸润的相关性。
在HCC中鉴定出前11个常见的差异表达基因,并选择RACGAP1进行进一步分析。RACGAP1在HCC组织中的表达明显高于正常组织。RACGAP1的上调与临床分期和不良预后相关。此外,RACGAP1的过表达与抑制性免疫细胞的浸润呈正相关。而且,我们推测RACGAP1可能通过YAP激活介导的免疫抑制促进HCC的肿瘤发生。
RACGAP1的过表达与HCC的不良预后和免疫浸润相关,这表明RACGAP1可能是HCC的一个分子靶点。